Role of Salbutamol and Furosemide in TTN

Role of Salbutamol and Furosemide in Transient Tachypnea of Newborn

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03208894

Enrollment

100

Registered

2017-07-06

Start date

2016-11-01

Completion date

2017-06-30

Last updated

2017-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient Tachypnea of the Newborn

Brief summary

to see the effects of slabutamol and IV furosemide in the treatment of transient tachypnea of newborn

Interventions

DRUGFurosemide Injection

efficacy of salbutamol and furosemide in TTN

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

1 Hours to 7 Days

Healthy volunteers

Inclusion criteria

* all newborn babies with clinically diagnosed TTN

Exclusion criteria

* babies less than 34 weeks babies with congenital malformations and CHD

Design outcomes

Primary

Measure	Time frame	Description
duration of oxygen requiremment in neonates having TTN.	upto 6 months	neonates will be subjected to treatment with furosemide and sabutamol and the duration of oxygen dependecy will be assessed.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026